MIL93
/ Beijing Mabworks Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
March 13, 2024
A Clinical Study of MIL93 in Solid Tumors.
(clinicaltrials.gov)
- P1 | N=228 | Recruiting | Sponsor: Beijing Mabworks Biotech Co., Ltd. | Trial completion date: Aug 2023 ➔ Aug 2025 | Trial primary completion date: Aug 2023 ➔ Aug 2025
Metastases • Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Oncology • Solid Tumor • CLDN18
March 17, 2023
A Clinical Study of MIL93 in Solid Tumors.
(clinicaltrials.gov)
- P1 | N=228 | Recruiting | Sponsor: Beijing Mabworks Biotech Co., Ltd. | Trial primary completion date: Feb 2023 ➔ Aug 2023
Metastases • Trial primary completion date • Gastrointestinal Cancer • Oncology • Solid Tumor • CLDN18
April 28, 2022
Safety, tolerability, pharmacokinetics and preliminary efficacy of MIL93, an anti-Claudin18.2 monoclonal antibody, in patients with advanced solid tumors: A phase 1 clinical study.
(ASCO 2022)
- P1 | "MIL93 had a favorable safety profile with no DLTs observed through 20mg/kg Q3W. Pts with CLDN18.2-positive gastric cancer responded to the treatment. Dose escalation and expansion in selected tumor types is currently underway."
Clinical • P1 data • PK/PD data • Anemia • Esophageal Cancer • Fatigue • Gallbladder Cancer • Gastric Cancer • Gastrointestinal Cancer • Hematological Disorders • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor • CLDN18 • CLDN8
December 13, 2022
Safety and preliminary efficacy of MIL93 in patients with advanced solid tumors: The monotherapy part of a phase 1 trial.
(ASCO-GI 2023)
- P1 | "MIL93 is a humanized afucosylated IgG1 monoclonal antibody targeting CLDN18.2 with enhanced ADCC function, which demonstrated superior activity compared with zolbetuximab in vitro and in vivo, respectively. MIL93 had a manageable and tolerable safety profile in patients with advanced solid tumors and preliminary anti-tumor activity in 2 heavily pretreated gastric cancer pts. Combination of MIL93 and standard treatment in selected tumor types is currently underway. Clinical trial information: NCT04671875."
Clinical • Metastases • Monotherapy • P1 data • Gastric Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CLDN18 • CLDN8
February 15, 2022
A Clinical Study of MIL93 in Solid Tumors.
(clinicaltrials.gov)
- P1 | N=228 | Recruiting | Sponsor: Beijing Mabworks Biotech Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Gastrointestinal Cancer • Oncology • Solid Tumor • CLDN18
December 17, 2020
A Clinical Study of MIL93 in Solid Tumors.
(clinicaltrials.gov)
- P1; N=228; Not yet recruiting; Sponsor: Beijing Mabworks Biotech Co., Ltd.
Clinical • New P1 trial • Gastrointestinal Cancer • Oncology • Solid Tumor
1 to 6
Of
6
Go to page
1